Observational studyCritical care science2026
Patterns and outcomes of real-world high-flow nasal cannula use: a multi-hospital retrospective cohort study.
Observational study in Critical care science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-flow nasal cannula in the real world: powerful support, hidden severity.Critical care science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize real-world high-flow nasal cannula use and outcomes.
methodsA retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 - 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 hours. We describe key measurements, including high-flow nasal cannula episode duration, intubation rates, and death or hospice discharge rates; secondary outcomes included intensive care unit admission, lengths of stay, and discharge location. We used adjusted hierarchical logistic regression to evaluate variation across hospitals.
results28,269 high-flow nasal cannula episodes from 17,519 individual patients over 19,313 hospitalizations were identified. Average high-flow nasal cannula use increased from 176 episodes/month in 2017 to 269 episodes/month by 2024 (p < 0.001). Median episode duration was 13.9 [interquartile range 4.3 - 36] hours, 24.5% of episodes were followed by intubation, and 29.3% by death or hospice discharge; 83.6% of high-flow nasal cannula use was escalation respiratory therapy, with the remainder used within 24 hours of extubation. Illness severity, admitting service, hospital, and unit type were associated with the odds of intubation and the duration of high-flow nasal cannula episodes; 16% of the variation in mortality and 20% of the variation in intubation were attributable to hospital-level variation.
conclusionHigh-flow nasal cannula is used in multiple hospital settings and contexts. The use of high-flow nasal cannula has increased between 2017 and 2025. Outcomes of high-flow nasal cannula use are influenced by both patient characteristics and the contexts in which it is used.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.